Please fill out the form below and we will gladly respond as soon as possible.
A landmark study just published in Nature Communications finally pinpointed the exact “cell of origin” for synovial sarcoma — a rare, primitive fibroblast that still carries embryonic markers (Hic1⁺ Pdgfra⁺ Lgr5⁺). Breaking 2025 Research: Read the entire article here. Learn more about our world-renowned registry efforts here.
The Synovial Sarcoma Foundation is excited to share that we are on site this week at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting in Boca Raton, Florida. This global event brings together leading researchers, oncologists, and experts in sarcoma to discuss the latest data-driven advancements in diagnosis, treatment, and clinical trials. Representing our Board of […]
The Synovial Sarcoma Foundation is pleased to highlight a significant milestone at the Children’s Hospital of Philadelphia (CHOP), where pediatric oncologist and Synovial Sarcoma Foundation Board Member, Dr. Theodore W. Laetsch, has been awarded a prestigious $1 million multi-year grant from the National Cancer Institute (NCI). This funding aims to accelerate research and treatment development […]
The Synovial Sarcoma Foundation is dedicated to supporting cutting-edge research that advances treatment options for this rare and aggressive cancer. Recent findings published in The EMBO Journal highlight a promising new strategy: using drug blockers to target a problematic protein involved in synovial sarcoma’s genetics. Synovial sarcoma primarily develops in soft tissues such as muscles […]
The Synovial Sarcoma Foundation is committed to staying informed on the latest research and developments in this rare and aggressive cancer. A recent market report indicates that the global synovial sarcoma market is projected to grow significantly, reaching an estimated USD 420 million by 2034 — up from USD 245 million in 2024, at a […]
We are proud to share that the Tumor Board now includes 42 participating institutions, strengthening our collective expertise and reach. These new members, along with our existing institutions, greatly enhance our ability to develop and implement cutting-edge, individualized treatment plans.
The Synovial Sarcoma Foundation is proud to announce a significant milestone in pediatric cancer research: Dr. Rachel Hurly, a dedicated pediatric oncology fellow from the Children’s Hospital of Philadelphia (CHOP), has been honored with the prestigious American Society of Clinical Oncology (ASCO) Young Investigator Award. Dr. Hurly conducts her research under the mentorship of Dr. Ted Laetsch at the Haldor Laboratory at the University of Pennsylvania, with support from the Synovial Sarcoma Fund.
Callan Spence isn’t waiting for progress—he’s chasing it down at full speed. At 20 years old, Callan is already a two-time synovial sarcoma fighter. But to see him now—helmet on, strapping into a 1,000-horsepower Lotus Exige—you’d never guess that this young man was once told he might not survive high school. In 2021, at just […]
On March 1, CHOP, in collaboration with Penn Medicine and the Synovial Sarcoma Foundation, hosted the first-ever national virtual conference dedicated solely to synovial sarcoma. More than 100 patients, caregivers, researchers, and clinicians attended the event, which featured expert presentations, research updates, and live discussions. The Synovial Sarcoma Foundation is dedicated to advancing research and […]
Thanks to the generosity of donors and supporters, the Fund has now raised over $2 million, accelerating research initiatives at CHOP and Penn Medicine. These funds are driving critical advancements in patient care, clinical trials, and the development of future treatment strategies. This milestone represents a major step forward in expanding Synovial Sarcoma research, allowing […]